This article was originally published in The Tan Sheet
Ross Products infant formula business remains untouched under new leadership and organization restructuring initiative slated to go into effect Aug. 1. Coinciding with the announced retirement of Abbott President and Chief Operating Officer Robert Parkinson, a new reporting structure will be set in place for the pharmaceuticals and medical products businesses. Ross will remain under the guidance of Senior VP Joy Amundson. The company's decision to leave Ross alone has opened speculation that the infant formula group could be a divestiture candidate
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC